OpenLB
Open Library of Bioscience
Advanced Search
Annals of hematology
Nov, 2024;103 (11): 4649-4660.

Clinical characteristics and prognosis of patients with newly diagnosed primary central nervous system lymphoma: a multicentre retrospective analysis.

Si-Jun Bai, Jian-Xia He, Yuan-Jun Zheng, Ye Geng, Yi-Nan Gao, Cai-Xia Zhang, Ya-Ru Wang, Li-Yuan Qin, Wen-Jun Wang, Lin-Hua Yang
Author Information
  1. Si-Jun Bai: Department of Hematology, Second Hospital of Shanxi Medical University, No.382 Wuyi Road, Xinghualing District, Taiyuan, Shanxi, 030000, China. ORCID
  2. Jian-Xia He: Department of Hematology, Shanxi Provincial People's Hospital, Taiyuan, 030000, China.
  3. Yuan-Jun Zheng: Department of Hematology, First Hospital of Shanxi Medical University, Taiyuan, 030000, China.
  4. Ye Geng: Department of Hematology, Shanxi Provincial People's Hospital, Taiyuan, 030000, China. ORCID
  5. Yi-Nan Gao: Department of Hematology, Shanxi Provincial People's Hospital, Taiyuan, 030000, China. ORCID
  6. Cai-Xia Zhang: Department of Hematology, Shanxi Provincial People's Hospital, Taiyuan, 030000, China. ORCID
  7. Ya-Ru Wang: Department of Hematology, Shanxi Provincial People's Hospital, Taiyuan, 030000, China.
  8. Li-Yuan Qin: Department of Hematology, Shanxi Provincial People's Hospital, Taiyuan, 030000, China.
  9. Wen-Jun Wang: Department of Hematology, Shanxi Provincial People's Hospital, Taiyuan, 030000, China.
  10. Lin-Hua Yang: Department of Hematology, Second Hospital of Shanxi Medical University, No.382 Wuyi Road, Xinghualing District, Taiyuan, Shanxi, 030000, China. yanglh5282@163.com. ORCID
PMID: 38761184 DOI: 10.1007/s00277-024-05797-7

Abstract

Bruton's tyrosine kinase inhibitors (BTKi) exhibit superior efficacy in relapsed/refractory primary central nervous system lymphoma (PCNSL), but few studies have evaluated patients with newly diagnosed PCNSL, and even fewer studies have evaluated differences in efficacy between treatment with BTKi and traditional chemotherapy. This study retrospectively analyzed the clinical characteristics of 86 patients with PCNSL and identified predictors of poor prognosis for overall survival (OS). After excluding patients who only received palliative care, 82 patients were evaluated for efficacy and survival. According to the induction regimen, patients were divided into the traditional chemotherapy, BTKi combination therapy, and radiotherapy groups; the objective response rates (ORR) of the three groups were 71.4%, 96.2%, and 71.4% (P = 0.037), respectively. Both median progression-free survival and median duration of remission showed statistically significant differences (P = 0.019 and P = 0.030, respectively). The median OS of the BTKi-containing therapy group was also longer than that of the traditional chemotherapy group (not reached versus 47.8 (32.5-63.1) months, P = 0.038).Seventy-one patients who achieved an ORR were further analyzed, and achieved an ORR after four cycles of treatment and maintenance therapy had prolonged OS (P = 0.003 and P = 0.043, respectively). In conclusion, survival, and prognosis of patients with newly diagnosed PCNSL are influenced by the treatment regimen, with the BTKi-containing regimen showing great potential.

Keywords

Bruton’s tyrosine kinase inhibitor Efficacy High-dose methotrexate Primary central nervous system lymphoma Prognosis

References

  1. Villano JL, Koshy M, Shaikh H et al (2011) Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 105(9):1414–1418. https://doi.org/10.1038/bjc.2011.357 [DOI: 10.1038/bjc.2011.357]
  2. Mendez JS, Ostrom QT, Gittleman H et al (2018) The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neurooncology 20(5):687–694. https://doi.org/10.1093/neuonc/nox187 [DOI: 10.1093/neuonc/nox187]
  3. Barajas RF, Politi LS, Anzalone N et al (2021) Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neurooncology 23(7):1056–1071. https://doi.org/10.1093/neuonc/noab020 [DOI: 10.1093/neuonc/noab020]
  4. Chen T, Liu Y, Wang Y et al (2022) Evidence-based expert consensus on the management of primary central nervous system lymphoma in China. J Hematol Oncol 15(1):136. https://doi.org/10.1186/s13045-022-01356-7 [DOI: 10.1186/s13045-022-01356-7]
  5. Loghavi S, Kanagal-Shamanna R, Khoury JD et al (2023) Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc, 100397. https://doi.org/10.1016/j.modpat.2023.100397 . 5th edition of the world health classification of tumors of the hematopoietic and lymphoid tissues. Advance online publication
  6. Lebrun L, Allard-Demoustiez S, Salmon I (2023) Pathology and new insights in central nervous system lymphomas. Curr Opin Oncol 35(5):347–356. https://doi.org/10.1097/CCO.0000000000000978 [DOI: 10.1097/CCO.0000000000000978]
  7. Woo HY, Chae SW, DO SI et al (2022) Clinicopathological characterization of primary diffuse large B-Cell lymphoma of the Central Nervous System. Anticancer Res 42(11):5601–5608. https://doi.org/10.21873/anticanres.16068 [DOI: 10.21873/anticanres.16068]
  8. Ferreri AJM, Calimeri T, Cwynarski K et al (2023) Primary central nervous system lymphoma. Nat Reviews Disease Primers 9(1):29. https://doi.org/10.1038/s41572-023-00439-0 [DOI: 10.1038/s41572-023-00439-0]
  9. Schaff LR, Grommes C (2022) Primary central nervous system lymphoma. Blood 140(9):971–979. https://doi.org/10.1182/blood.2020008377 [DOI: 10.1182/blood.2020008377]
  10. Yuan Y, Ding T, Wang S et al (2021) Current and emerging therapies for primary central nervous system lymphoma. Biomark Res 9(1):32. https://doi.org/10.1186/s40364-021-00282-z [DOI: 10.1186/s40364-021-00282-z]
  11. Shibamoto Y, Ogino H, Hasegawa M et al (2005) Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys 62(3):809–813. https://doi.org/10.1016/j.ijrobp.2004.12.043 [DOI: 10.1016/j.ijrobp.2004.12.043]
  12. Houillier C, Soussain C, Ghesquières H et al (2020) Management and outcome of primary CNS lymphoma in the modern era: an LOC network study. Neurology 94(10):e1027–e1039. https://doi.org/10.1212/WNL.0000000000008900 [DOI: 10.1212/WNL.0000000000008900]
  13. Lewis KL, Cheah CY (2021) Non-covalent BTK inhibitors-the New BTKids on the Block for B-Cell malignancies. J Personalized Med 11(8):764. https://doi.org/10.3390/jpm11080764 [DOI: 10.3390/jpm11080764]
  14. Leitinger DE, Kaplan DZ (2022) BTK inhibitors in Haematology: Beyond B Cell malignancies. Transfus Med Rev 36(4):239–245. https://doi.org/10.1016/j.tmrv.2022.06.009 [DOI: 10.1016/j.tmrv.2022.06.009]
  15. Bonzheim I, Sander P, Salmerón-Villalobos J et al (2022) The molecular hallmarks of primary and secondary vitreoretinal lymphoma. Blood Adv 6(5):1598–1607. https://doi.org/10.1182/bloodadvances.2021004212 [DOI: 10.1182/bloodadvances.2021004212]
  16. Pal Singh S, Dammeijer F, Hendriks RW (2018) Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer 17(1):57. https://doi.org/10.1186/s12943-018-0779-z [DOI: 10.1186/s12943-018-0779-z]
  17. Cetin GO, Baris IC, Caner V et al (2016) Mutational status of EZH2 and CD79B hot spots in mature B-cell non-hodgkin’s lymphomas: novel CD79B variations have been revealed. Eur Rev Med Pharmacol Sci 20(5):830–836 [PMID: 27010137]
  18. Wu K, Zhang H, Fu Y et al (2018) TLR4/MyD88 signaling determines the metastatic potential of breast cancer cells. Mol Med Rep 18(3):3411–3420. https://doi.org/10.3892/mmr.2018.9326 [DOI: 10.3892/mmr.2018.9326]
  19. Ollila TA, Olszewski AJ (2018) Extranodal diffuse large B cell lymphoma: molecular features, prognosis, and risk of Central Nervous System recurrence. Curr Treat Options Oncol 19(8):38. https://doi.org/10.1007/s11864-018-0555-8 [DOI: 10.1007/s11864-018-0555-8]
  20. Nagane M (2022) Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives. Japanese J Clin Hematol 63(9):1145–1156. https://doi.org/10.11406/rinketsu.63.1145 [DOI: 10.11406/rinketsu.63.1145]
  21. Grommes C, Tang SS, Wolfe J et al (2019) Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood 133(5):436–445. https://doi.org/10.1182/blood-2018-09-875732 [DOI: 10.1182/blood-2018-09-875732]
  22. Soussain C, Choquet S, Blonski M et al (2019) Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. European journal of cancer (Oxford, England: 1990), 117, 121–130. https://doi.org/10.1016/j.ejca.2019.05.024
  23. Abrey LE, Batchelor TT, Ferreri AJ, International Primary CNS Lymphoma Collaborative Group (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncology: Official J Am Soc Clin Oncol 23(22):5034–5043. https://doi.org/10.1200/JCO.2005.13.524 [DOI: 10.1200/JCO.2005.13.524]
  24. Batchelor TT (2016) Primary central nervous system lymphoma. Hematology. American Society of Hematology. Education Program, 2016(1), 379–385. https://doi.org/10.1182/asheducation-2016.1.379
  25. Tang D, Chen Y, Shi Y et al (2022) Epidemiologic Characteristics, prognostic factors, and treatment outcomes in primary Central Nervous System Lymphoma: a SEER-Based study. Front Oncol 12:817043. https://doi.org/10.3389/fonc.2022.817043 [DOI: 10.3389/fonc.2022.817043]
  26. Chen C, Sun P, Sun XQ et al (2023) Primary treatment and recent survival trends in patients with primary diffuse large B-cell lymphoma of central nervous system, 1995–2016: a population-based SEER analysis. Hematol Oncol 41(2):248–256. https://doi.org/10.1002/hon.2918 [DOI: 10.1002/hon.2918]
  27. van der Meulen M, Dinmohamed AG, Visser O et al (2017) Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989–2015. Leukemia 31(8):1822–1825. https://doi.org/10.1038/leu.2017.128 [DOI: 10.1038/leu.2017.128]
  28. Farrall AL, Smith JR (2021) Changing incidence and survival of primary Central Nervous System Lymphoma in Australia: a 33-Year National Population-based study. Cancers 13(3):403. https://doi.org/10.3390/cancers13030403 [DOI: 10.3390/cancers13030403]
  29. Fukumura K, Kawazu M, Kojima S et al (2016) Genomic characterization of primary central nervous system lymphoma. Acta Neuropathol 131(6):865–875. https://doi.org/10.1007/s00401-016-1536-2 [DOI: 10.1007/s00401-016-1536-2]
  30. Nayyar N, White MD, Gill CM et al (2019) MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. Blood Adv 3(3):375–383. https://doi.org/10.1182/bloodadvances.2018027672 [DOI: 10.1182/bloodadvances.2018027672]
  31. Lee JH, Jeong H, Choi JW et al (2017) Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis. Sci Rep 7(1):1785. https://doi.org/10.1038/s41598-017-01998-5 [DOI: 10.1038/s41598-017-01998-5]
  32. Ferreri AJ, Blay JY, Reni M et al (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncology: Official J Am Soc Clin Oncol 21(2):266–272. https://doi.org/10.1200/JCO.2003.09.139 [DOI: 10.1200/JCO.2003.09.139]
  33. Abrey LE, Ben-Porat L, Panageas KS et al (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncology: Official J Am Soc Clin Oncol 24(36):5711–5715. https://doi.org/10.1200/JCO.2006.08.2941 [DOI: 10.1200/JCO.2006.08.2941]
  34. Liu CJ, Lin SY, Yang CF et al (2020) A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma. Cancer Med 9(6):2134–2145. https://doi.org/10.1002/cam4.2872 [DOI: 10.1002/cam4.2872]
  35. Shen J, Liu J (2022) Bruton’s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: a mini-review. Front Oncol 12:1034668. https://doi.org/10.3389/fonc.2022.1034668 [DOI: 10.3389/fonc.2022.1034668]
  36. Grommes C, Pastore A, Palaskas N et al (2017) Ibrutinib unmasks critical role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discov 7(9):1018–1029. https://doi.org/10.1158/2159-8290.CD-17-0613 [DOI: 10.1158/2159-8290.CD-17-0613]
  37. Renaud L, Bossard JB, Carpentier B et al (2021) Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Eur J Haematol 107(3):370–373. https://doi.org/10.1111/ejh.13667 [DOI: 10.1111/ejh.13667]
  38. Lauer EM, Waterhouse M, Braig M et al (2020) Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: a retrospective single-centre analysis. Br J Haematol 190(2):e110–e114. https://doi.org/10.1111/bjh.16759 [DOI: 10.1111/bjh.16759]
  39. Lewis KL, Chin CK, Manos K et al (2021) Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. Br J Haematol 192(6):1049–1053. https://doi.org/10.1111/bjh.16946 [DOI: 10.1111/bjh.16946]
  40. Estupiñán HY, Berglöf A, Zain R et al (2021) Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front cell Dev Biology 9:630942. https://doi.org/10.3389/fcell.2021.630942 [DOI: 10.3389/fcell.2021.630942]
  41. Munir T, Brown JR, O’Brien S et al (2019) Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol 94(12):1353–1363. https://doi.org/10.1002/ajh.25638 [DOI: 10.1002/ajh.25638]
  42. Lionakis MS, Dunleavy K, Roschewski M et al (2017) Inhibition of B cell receptor signaling by Ibrutinib in primary CNS Lymphoma. Cancer Cell 31(6):833–843e5. https://doi.org/10.1016/j.ccell.2017.04.012 [DOI: 10.1016/j.ccell.2017.04.012]
  43. Zhang Y, Li Y, Zhuang Z et al (2021) Preliminary evaluation of Zanubrutinib-Containing regimens in DLBCL and the cerebrospinal fluid distribution of Zanubrutinib: a 13-Case Series. Front Oncol 11:760405. https://doi.org/10.3389/fonc.2021.760405 [DOI: 10.3389/fonc.2021.760405]
  44. Song Y, Deng L, Zhang B et al (2021) Preliminary results of orelabrutinib concentrations in peripheral blood and cerebrospinal fluid in patients with relapsed/refractory primary or secondary CNS lymphoma. In CSCO, 24th Annual Meeting
  45. Hillmen P, Brown JR, Eichhorst BF et al (2020) ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Future Oncol (London England) 16(10):517–523. https://doi.org/10.2217/fon-2019-0844 [DOI: 10.2217/fon-2019-0844]
  46. Tam CS, Opat S, D’Sa S et al (2020) A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood 136(18):2038–2050. https://doi.org/10.1182/blood.2020006844 [DOI: 10.1182/blood.2020006844]
  47. Dhillon S (2021) Orelabrutinib: first approval. Drugs 81(4):503–507. https://doi.org/10.1007/s40265-021-01482-5 [DOI: 10.1007/s40265-021-01482-5]
  48. Zhao S, Liu Y, Zhu Z et al (2022) Orelabrutinib, Rituximab, and high-dose methotrexate (HD-MTX) in newly diagnosed primary Central Nervous System Lymphoma (PCNSL): a retrospective analysis on Efficacy, Safety, and Biomarker. Blood 140(Supplement 1):1338–1339 [DOI: 10.1182/blood-2022-165710]
  49. Vu K, Mannis G, Hwang J et al (2019) Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma. Br J Haematol 186(1):180–183. https://doi.org/10.1111/bjh.15787 [DOI: 10.1111/bjh.15787]
  50. Faivre G, Butler MJ, Le I et al (2019) Temozolomide as a single Agent maintenance therapy in Elderly patients with primary CNS lymphoma. Clin Lymphoma Myeloma Leuk 19(10):665–669. https://doi.org/10.1016/j.clml.2019.05.012 [DOI: 10.1016/j.clml.2019.05.012]

MeSH Term

Humans
Retrospective Studies
Male
Female
Middle Aged
Central Nervous System Neoplasms
Aged
Adult
Prognosis
Aged, 80 and over
Agammaglobulinaemia Tyrosine Kinase
Antineoplastic Combined Chemotherapy Protocols
Protein Kinase Inhibitors
Survival Rate
Lymphoma

Chemicals

Agammaglobulinaemia Tyrosine Kinase
Protein Kinase Inhibitors
BTK protein, human
Journal Article Multicenter Study

Word Cloud

Created with Highcharts 10.0.0patientsP = 0PCNSLsurvivalBTKiefficacycentralnervoussystemevaluatednewlydiagnosedtreatmenttraditionalchemotherapyprognosisOSregimentherapyORRrespectivelymediantyrosinekinaseprimarylymphomastudiesdifferencesanalyzedcharacteristicsgroups714%BTKi-containinggroupachievedBruton'sinhibitorsexhibitsuperiorrelapsed/refractoryevenfewerstudyretrospectivelyclinical86identifiedpredictorspooroverallexcludingreceivedpalliativecare82Accordinginductiondividedcombinationradiotherapyobjectiveresponseratesthree962%037progression-freedurationremissionshowedstatisticallysignificant019030alsolongerreachedversus478325-631months038Seventy-onefourcyclesmaintenanceprolonged003043conclusioninfluencedshowinggreatpotentialClinicallymphoma:multicentreretrospectiveanalysisBruton’sinhibitorEfficacyHigh-dosemethotrexatePrimaryPrognosis

Similar Articles

Cited By